Kisspeptin-10 for Men: Studies and Label Warnings
Studies of Kisspeptin-10 that enrolled only men, what they measured, and what is still unproven.
- Strongest evidence
- Human RCT
- Studies enrolling only men
- 4
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
Studies that enrolled only men
Each row is a study whose participants were described as men only. Results from one sex are not evidence for the other. Studies of animals and cells are not included.
| Study | Design | Population | Dose | First outcome |
|---|---|---|---|---|
| European journal of endocrinology 2026, PMID 42549827 | Human RCT | Healthy men (3 studies: acute dose-response, 5-day continuous, 12-day intermittent) | 1.25-10.0 nmol/kg/h acute; 150 nmol/h daily 8 h for 12 days | LH, FSH and testosterone (acute): Acute kisspeptin-10 infusions raised LH, FSH and testosterone dose-dependently versus vehicle (P < .0001). |
| The Journal of clinical endocrinology and metabolism 2022, PMID 35244717 | Human RCT | Healthy eugonadal men (plus in-vitro human bone cells) | Not stated | Bone formation marker: Total osteocalcin rose a maximum of 20.3% after kisspeptin (P = .021). |
| The Journal of clinical investigation 2017, PMID 28112678 | Human RCT | Healthy heterosexual young men | Not stated | Limbic brain activity and mood: Kisspeptin enhanced limbic brain activity in response to sexual and couple-bonding stimuli. |
| The Journal of clinical endocrinology and metabolism 2011, PMID 21632807 | Human controlled trial | Healthy men (n=4 to 6 per dose group) | iv bolus 0.01-3.0 ug/kg; infusion 1.5-4 ug/kg/h | Testosterone during infusion: At 4 ug/kg/h for 22.5 h, LH rose from 5.4 to 20.8 IU/liter and testosterone from 16.6 to 24.0 nmol/liter. |
Peptides studied in men, compared
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Men's health context
MedlinePlus lists low testosterone among conditions that affect only men.[14]
Studies that enrolled only men
In healthy men, kisspeptin-10 given as an intravenous bolus produced a dose-dependent rise in LH, and a 3 μg/kg bolus gave a smaller response than 1 μg/kg.[4]
Subcutaneous kisspeptin-10 infusion raised testosterone in healthy men, and the gonadotropin rises were sustained for 12 days.[1]
In healthy heterosexual young men, kisspeptin increased limbic brain activity to sexual and bonding stimuli and lowered negative mood.[3]
In healthy men with normal testosterone, short-term kisspeptin exposure increased a bone-formation marker without raising resorption markers.[2]
What is missing
A PubMed search on 2 Oct 2026 for kisspeptin with men, male, testosterone or hypogonadism words in humans returned 90 records, but all the male studies cached here enrolled healthy men and none a hypogonadal population.
Calculated from source web/src/data/evidence/kisspeptin.json searches; date 2026-10-02; query kisspeptin[tiab] AND humans[mh] AND (men[tiab] OR male[tiab]) AND (testosterone[tiab] OR hypogonadism[tiab]); count 90; cached male studies 4; hypogonadal cached 0. Formula: count reported as recorded
Other peptides people research for men
All peptides for men, comparedCommon questions
Has Kisspeptin-10 been studied in men?
4 studies we summarise enrolled only men. Results from one sex are not evidence for the other.
Is Kisspeptin-10 approved for men?
No. Kisspeptin-10 is not FDA approved for any use in men or anyone else.
What is the kisspeptin dosage for men?
No label or approved dosage exists; the studies used per-kilogram or hourly infusion amounts in healthy men, with subcutaneous infusions of 1.25 to 10.0 nmol/kg/h in the dose-response arm.[1]
More on Kisspeptin-10
Sources
- 1Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
- 2Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men.The Journal of clinical endocrinology and metabolism · 2022PMID 35244717Accessed 2 Oct 2026
- 3Kisspeptin modulates sexual and emotional brain processing in humans.The Journal of clinical investigation · 2017PMID 28112678Accessed 2 Oct 2026
- 4Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.The Journal of clinical endocrinology and metabolism · 2011PMID 21632807Accessed 2 Oct 2026
- 5PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND humans[mh] (110 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: (kisspeptin[tiab]) AND humans[mh] AND (randomized controlled trial[pt] OR clinical trial[pt]) (54 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: kisspeptin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) AND humans[mh] (13 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: kisspeptin[tiab] AND humans[mh] AND (men[tiab] OR male[tiab]) AND (testosterone[tiab] OR hypogonadism[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: kisspeptin[tiab] AND (menopaus*[tiab] OR postmenopaus*[tiab]) (89 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: kisspeptin[tiab] AND (liver[tiab] OR NAFLD[tiab] OR hepatic[tiab]) (68 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin-54"[tiab] OR kisspeptin[tiab]) AND humans[mh] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (75 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 12PubMed search: (kisspeptin[tiab]) AND (nausea[tiab] OR flush*[tiab] OR "injection site"[tiab] OR headache[tiab] OR "ovarian hyperstimulation"[tiab] OR tachyphylaxis[tiab] OR desensiti*[tiab]) AND humans[mh] (60 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 13PubMed search: (kisspeptin[tiab] OR "kisspeptin-54"[tiab] OR "kisspeptin-10"[tiab]) AND ("clinical trial"[pt] OR "randomized controlled trial"[pt]) AND (women[tiab] OR men[tiab]) AND (adverse[tiab] OR tolerat*[tiab] OR "side effects"[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 14Official web pageOfficial web page · web page
Found an error? Report a correction.